
    
      A Phase 1, open-label, dose-escalation study designed to evaluate the safety and tolerability
      of RO7296682 in participants with advanced and/or metastatic solid tumors. RO7296682 will be
      administered by intravenous (IV) infusion every 3 weeks. This entry-into-human study is
      divided into a dose-escalation stage (Part A) and a dose expansion stage (Part B).
    
  